# 1. Financial Performance ## A. Key Figures * Consolidated Revenue: ₹2,167 Cr (+16.6%) · Hospital Revenue: ₹1,838 Cr (+18.6%) · Diagnostics Revenue: ₹329 Cr (+6.3%) * **Operating EBITDA:** **₹491 Cr** (+2%) · **Margin:** **22.7%** (up from 20.4%) * **PAT before Exceptionals:** **₹254 Cr** (+2%) * Net Debt: ₹1,869 Cr (Net Debt/EBITDA: 0.92x) ## B. Revenue Growth * **Strong Operational Momentum:** Healthy start to FY’26 with robust revenue growth across both hospital and diagnostics businesses, driven by volume and value expansion. * **Growth Drivers:** 9% operating revenue growth fueled by **5% volume** and **4% value** gains; underlying growth remains solid at 3% after adjusting for prior-year one-off. * **ARPOB Expansion:** Revenue per operating bed rising on higher day care, OPD, and robotic surgeries, with minimal reliance on price hikes (**only 3%**). * **Strategic Revenue Stream:** Gleneagles agreement adds **3% of net revenue** as low-cost service fee, expected to flow directly to EBITDA and support margin scalability. ## C. EBITDA Margins * **Sustainable Margin Expansion:** Hospital segment delivered **nearly 300 bps YoY EBITDA margin improvement**, with no one-off benefits, signaling durable operating leverage. * **Efficiency Gains:** Margin progression underpinned by operational efficiencies, particularly at Escorts Delhi Hospital (**15–17% margin**), with further upside potential. * **Gleneagles Impact:** Incremental EBITDA from Gleneagles contribution will be accretive, though full-year margin expansion capped at **less than 100 bps**. * **Clean Margin Performance:** No one-off impacts in current quarter; diagnostics margin analysis includes other income for comparability. ## D. Net Debt Position * **Elevated Leverage Post-Acquisitions:** Sharp rise in net debt and **92x Net Debt/EBITDA** reflects funding of **5% PE stake in Agilus Diagnostics** and **Fortis brand acquisition**, both strategic moves to consolidate control and scale. --- # 2. Hospital & Diagnostics Revenue ## A. Key Figures * **Diagnostics Gross Revenue:** **₹369 Cr** (+7% YoY) · **₹344 Cr** prior year * Diagnostics Operating EBITDA Margin: **23%** (+1600 bps YoY) · **18.7%** prior year (ex-one-offs) * **International Revenue:** **₹154 Cr** (+21% YoY), **~8%** of total revenue * **Ludhiana EBITDA Margin:** >**20%** · **FMRI & Anandpur:** >**25%** * **Gleneagles Incremental Revenue:** **₹20–25 Cr** (~3% of net revenue), not in initial FY26 guidance ## B. Hospital Revenue Mix * **Digital Channel Softness:** Digital revenue growth slowed to low single digits, with its share of Hospital revenues declining meaningfully year-on-year. * **B2B Shift Continues:** Revenue mix has modestly pivoted toward B2B (49%), reflecting strategic client diversification. * **Payer Mix Improvement:** Early gains in PPA and international volumes driving slight uplift; further progress expected to be incremental. * **Strong Unit-Level Margins:** Multiple hospitals now exceed 20% EBITDA margin, signaling operational maturity and pricing power. ## C. Diagnostics Revenue Trends * **Margin Rebound Achieved:** Diagnostics EBITDA margin has sharply recovered to 22–23% (net revenue basis), supported by scale and cost discipline. * **Growth Moderation:** Reported net revenue growth lags underlying demand due to gross-to-net adjustments, though high-single-digit to low-10% growth remains the near-term outlook. * **Growth Trajectory:** Revenue expected to accelerate into early double digits over the next 6–8 quarters as volume and pricing levers align. ## D. International Revenue * **Robust International Growth:** International revenue expanded at a strong double-digit pace, maintaining an ~8% revenue contribution with absolute growth ahead. * **Strategic Clustering:** Gleneagles facilities in Hyderabad and Chennai form a new growth cluster, offering expansion potential despite current O&M fee-only structure. * **Unplanned Revenue Upside:** Incremental ₹20–25 Cr from Gleneagles operations to be added to FY26 results outside original guidance, enhancing top-line visibility. --- # 3. Occupancy & Capacity Expansion ## A. Key Figures * **Operational Facilities & Beds:** **33 facilities** with **>5,700 beds** across 11 states * **Hospital Occupancy:** **69% network-wide** (up from 67%) · **2,928 occupied beds** (+8%) * **Bed Expansion Plan:** **~900 beds** to be added in FY26, **~50% expected operational** this year * **Incremental Revenue Potential:** **≥₹1,500 Cr** from new beds in FY26–27 * **O&M Beds:** **~1,300 beds** under management (including Gleneagles) * **Robotic Systems:** **15 installed**, **4 planned** this year * **Capex per Robot:** **₹12 Cr** per da Vinci · **₹5 Cr** per ortho robot ## B. Bed Utilization & Performance Trends * **Broad-Based Recovery:** Network-wide occupancy improved to ~70%, with strong performances at FMRI (80%), Faridabad (>80%), and Noida (76%) supporting margin expansion. * **High-Utilization Efficiency:** Hospitals above 75–80% occupancy show stable ALOS with minor improvement, reflecting operational discipline and clinical throughput. * **Underperforming Units Showing Resilience:** BG Road (56–57%) and Mulund (<60%) maintain **EBITDA margins above 20%**, indicating high-quality revenue despite lower volumes. * **Punjab Cluster Strength:** Jalandhar acquisition integrated successfully; Amritsar and Mohali delivering strong results with expansion underway. ## C. Brownfield Expansion & Strategic Growth * **Dominant Punjab Footprint:** Acquisition of Jalandhar hospital expands Punjab bed count to **~1,000**, creating a leading regional cluster with **450+ beds planned** in Mohali, Jalandhar, and Amritsar. * **Faster Ramp-Up via Brownfield Model:** All expansions are brownfield, enabling quicker revenue contribution — **~600 beds expected to fully contribute in FY26–27**. * **Strategic Asset Light Growth:** Gleneagles O&M agreement adds **~700 beds** across 5 hospitals and 1 clinic under management, expanding reach without P&L consolidation. ## D. New Facility Ramp-up * **Manesar Outperforming Expectations:** Generating **>₹11 Cr/month** in revenue and ramping faster than anticipated; breakeven expected upon reaching **+₹2 Cr/month**. * **Premium Patient Mix at New Sites:** Faridabad, FMRI, and Noida attracting high-specialty patients from launch, supporting strong initial utilization and revenue quality. --- # 4. Clinical & Service Mix ## A. Key Figures * Hospital ARPOB: ₹2.65 Cr per annum (+10.2%) from ₹2.41 Cr in Q1 FY25 * **Oncology Revenue Growth:** **+28% YoY** · **CAGR of 27–28%** over recent years * **Oncology Revenue Contribution:** **19–20%** of total revenue (up from 1%) * **Robotic Surgeries Growth:** **+75% YoY** in volume and procedures * **Robots Deployed:** **>14** across network ## B. Oncology Growth * **Core Growth Driver:** Oncology has emerged as a high-growth, high-margin engine with **sustained 27–28% CAGR**, now representing a **core 20% of revenue**. * **Value Accretion:** Revenue per occupied bed (ARPOB) expansion driven by **shift to higher-value oncology treatments** and improved specialty mix. * **Strategic Expansion:** Growth trajectory expected to continue via rollout in hospitals lacking dedicated oncology services. ## C. Robotic Surgeries * **High-Tech Adoption:** Robotic surgery volumes surged **75% YoY**, supported by deployment of **over 14 systems** and growing clinical acceptance. * **Payer Mix Shift:** Institutional payer contribution declined to **3%** from 9% YoY, indicating greater self-pay or retail patient utilization. ## D. Specialty Case Mix * **Clinical Quality Uplift:** Strategic hiring in **oncology, cardiac, O&G, and renal sciences** has enhanced service depth and driven positive case mix. * **Technology Integration:** Inpatient EMR rollout at Fortis FEHI enables **real-time clinician access**, improving care coordination and operational efficiency. * **International Demand:** **Oncology, cardiac, and neurology** are key specialties attracting cross-border patients, reinforcing clinical reputation. --- # 5. Diagnostics Volume & Portfolio ## A. Key Figures * **Gross Revenue:** **₹368.8 Cr** Agilus Diagnostics (+7.4% YoY, +5.8% QoQ) · Prior: ₹348.5 Cr * Operating EBITDA: **₹84.7 Cr** Agilus Diagnostics (+53% YoY, +35% QoQ) · Margin: **23%** (+690 bps YoY, +500 bps QoQ) * **Test Volume:** **10.1 Mn tests** conducted (+4% YoY, +4% QoQ) · Prior: 9.57 Mn ## B. Test Volume Growth * **Strong Volume & Revenue Momentum:** Robust double-digit EBITDA growth on the back of volume expansion and operational leverage, with **5% volume growth** and **4% revenue per patient growth** driving a combined **9% total revenue growth potential**. * **Network Expansion Accelerating:** Added **10 new labs and 160+ customer touch points** in the quarter, boosting reach and supporting future volume capture. ## C. Wellness & Preventive Care * **Wellness Segment Gaining Traction:** Preventive care revenues grew **4%**, now representing **12% of operating revenues**, with strong demand for health check-up packages across units. * **Stable Revenue Mix, B2C Upside Potential:** Current **B2C:B2B mix at 51:49** expected to remain stable, though B2C share could expand with network productivity improvements. * **Core Testing Dominates Portfolio:** Revenue split remains anchored in routine testing (**54%**), followed by specialized tests (**34%**) and wellness (**12%**). ## D. Product Innovation * **Genomics Outperforms with Strategic Focus:** Portfolio grew **17% YoY**, fueled by investments in **next-generation diagnostics** and targeted oncology offerings. * **Innovation Pipeline Active:** Launched **~30 new tests** in the quarter, including the **Digitrack Bundle** for hematological malignancies and **comprehensive drug assay panels** for allergy profiling. * **Selective Inorganic Growth on Radar:** Open to **acquisitions across geographies** where strategic fit and scale-building opportunities exist; evaluated case-by-case. --- # 6. Risks & Asset Quality ## A. Key Figures * **Underperforming Assets:** **11 hospitals** with >20% EBITDA margin, contributing **75% of Hospital revenues** · **10 hospitals** contributed **73%** in prior year * Gleneagles Margins: Currently **3.5% or 4%** EBITDA margin under O&M arrangement * **Jaipur Performance:** Achieved **double-digit EBITDA margin** post-recovery ## B. Underperforming Hospitals * **Concentration & Improvement:** High-margin contribution from a shrinking core of top performers, with strong operational gains in **Ludhiana, FMRI, Anandpur, and Jaipur** driving margin expansion. * **Gleneagles Turnaround Strategy:** O&M model focused on unlocking value via **supply chain synergies and operational efficiencies**, though low current margins raise asset quality concerns. * **Acquisition Discipline:** Fortis emphasizes cautious, transparent, and arm’s-length approach to M&A amid scrutiny over valuation of underperforming assets. ## C. Brand Transition Impact * **SRL Brand Reacquired:** Agilus regains full rights to the legacy SRL name, reversing court-mandated rebranding that disrupted brand continuity. * **Rebranding Strategy:** SRL will be fully transitioned to Agilus with **clear communication of legacy**, enhancing trust and market positioning without dual branding. --- # 7. Guidance & Outlook ## A. Key Figures * **Robotic Surgery Growth:** **~50%** expected next year (vs. 75% current) * **ARPOB Growth:** **5%–6%** guided for normal course * **Diagnostics EBITDA Margin:** **22%–23%** expected full-year range * **Consolidated EBITDA Margin Expansion:** **200 bps** annual guidance maintained ## B. Revenue Projections * **Sustained Growth Trajectory:** Hospital and Diagnostics businesses remain on positive growth path, supported by cluster strategy and strong balance sheet. * **Robotic Surgery Momentum:** Growth set to remain robust next year despite anticipated moderation from exceptional current pace. ## C. Margin Expansion Plan * **Margin Resilience:** Full-year diagnostics margin outlook stable at 22–23%, with expected seasonal fluctuation across quarters. * **Expansion Drivers:** 200 bps margin improvement underpinned by **favorable case mix**, **new facilities**, and **recently introduced treatment modalities**. * **Guidance Discipline:** Despite strong Q1 performance and brownfield advantages, company holds margin guidance unchanged, signaling conservative posture.